Loading...
Please wait, while we are loading the content...
Similar Documents
Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials
| Content Provider | Scilit |
|---|---|
| Author | Katz, Eva G. Hauber, Brett Gopal, Srihari Fairchild, Angie Pugh, Amy Weinstein, Rachel B. Levitan, Bennett S. |
| Copyright Year | 2016 |
| Abstract | Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials Eva G Katz,1 Brett Hauber,2 Srihari Gopal,3 Angie Fairchild,2 Amy Pugh,4 Rachel B Weinstein,3 Bennett S Levitan3 1Janssen Research & Development, LLC, Raritan, NJ, 2RTI Health Solutions, Research Triangle Park, NC, 3Janssen Research & Development, LLC, Titusville, NJ, 4The University of California, San Francisco (UCSF), CA, USA Purpose: To quantify clinical trial participants’ and investigators’ judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence.Methods: Discrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic. Respondents were asked to choose between hypothetical antipsychotic profiles defined by efficacy, safety, and mode of administration. Data were analyzed using random-parameters logit and probit models.Results: Patients (N=214) and physicians (N=438) preferred complete improvement in positive symptoms (severe to none) as the most important attribute, compared with improvement in any other attribute studied. Both respondents preferred 3-month and 1-month injectables to oral formulation (P30%. For patients, adherent: 10.1% (95% CI: 6.1–14.1), nonadherent: the change in efficacy studied was regarded as unimportant.Conclusion: Improvement in positive symptoms was the most important attribute. Patients and physicians preferred LAIs over oral antipsychotics, with physicians showing a greater preference for 3-month over 1-month LAI. Physicians and patients were willing to accept reduced efficacy in exchange for switching a patient from an oral formulation to a LAI. Keywords: benefit–risk assessment, long-acting injectable, patient preference, physician preference, schizophrenia, survey |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085312/pdf https://www.dovepress.com/getfile.php?fileID=33105 |
| Ending Page | 2139 |
| Page Count | 13 |
| Starting Page | 2127 |
| ISSN | 1177889X |
| DOI | 10.2147/ppa.s114172 |
| Journal | Patient preference and adherence |
| Volume Number | 10 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2016-10-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Patient Preference and Adherence Substance Abuse Benefit–risk Assessment Long-acting Injectable Patient Preference Physician Preference Schizophrenia Survey |
| Content Type | Text |
| Resource Type | Article |
| Subject | Social Sciences Pharmacology, Toxicology and Pharmaceutics Health Policy |
